Review Article
Diagnostic and Prognostic Roles of Thrombospondin-2 in Digestive System Cancers
Table 2
Characteristics of included studies related to prognosis.
| | First author | Year | Journal | Location | Disease | Sample size | Sample | OS HR (95% CI) | DFS HR (95% CI) | NOS |
| | Peng [37] | 2018 | Annals of Surgical Oncology | China | Pancreatic cancer | 263 | Blood | 1.822 (1.389-2.389) | — | 6 | | Lin [28] | 2015 | American Journal of Translational Research | China | Rectal cancer | 172 | Tissue | — | 0.327 (0.160-0.670) | 7 | | Tian [39] | 2018 | Official Journal of the Balkan Union of Oncology | China | Colorectal cancer | 100 | Tissue | 4.219 (1.795-9.901) | — | 6 | | Zhang [27] | 2017 | British Journal of Cancer | China | Hepatocellular carcinoma | 44 | Blood | 2.070 (0.896-4.779) | 2.69 (1.203-6.012) | 6 | | Liu [11] | 2020 | Molecular Cancer Therapeutics | USA | Colorectal cancer | 149 | Blood | 1.49 (1.22-1.83) | — | 7 | | Fei [10] | 2017 | Oncotarget | China | Colorectal cancer | 402 | Blood | 1.261 (0.776-2.05) | — | 6 | | Byrling [40] | 2020 | Journal of Translational Medicine | Europe | Cholangiocarcinoma | 59 | Tissue | 3.34 (0.94-11.8) | 3.95 (1.09-14.3) | 9 | | Nixon [41] | 2013 | Clinical Cancer Research | USA | Pancreatic cancer | 159 | Blood | 1.6 (1.1-2.1) | — | 7 | | Sun [29] | 2014 | Molecular Cancer | China | Gastric cancer | 129 | Tissue | 0.51 (0.31-0.85) | — | 8 | | Liu [42] | 2015 | Molecular Cancer Therapeutics | USA | Colorectal cancer | 49 | Blood | 2.9 (1.44-5.04) | — | 5 |
|
|
NOS: Newcastle-Ottawa scale; OS: overall survival; DFS: disease-free survival.
|
